Alpha memo: resveratrol exercise protocol mismatch

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Rename the memo to reflect the actual research signal, e.g., 'Resveratrol + exercise: context-dependent signal in older adults' or 'Resveratrol + exercise: population and dose boundary in older adults', so that the title aligns with the receipts (resveratrol anchor preserved; exercise modality consistent; population/dose as the contrast).
2. Remove or correct 'matched RCT' for Receipt 2 in the abstract; describe it as a randomized, placebo-controlled trial in healthy inactive aged men.
3. Strengthen the moderator hypothesis sentence to make it clear which dimensions differ across the receipts (population: functional limitations vs. healthy inactive; dose: 250 mg vs. 500-1000 mg; duration: 8 weeks vs. 12 weeks) rather than treating them as a single 'protocol mismatch.'

Major issues

• The title says 'resveratrol exercise protocol mismatch' but the substantive signal is better described as a context/population mismatch (functional limitations vs. healthy aged men, dose 500-1000 mg vs. 250 mg). The current framing centers on 'protocol mismatch' which understates the population-anchor difference that the memo itself flags as the moderator hypothesis.

Minor issues

• The abstract claims the second RCT is 'matched' ('a separate matched RCT in healthy aged men') but Receipt 2 is not described as a matched trial in the source bundle; 'matched' should be removed or replaced with descriptive context.
• The phrase 'the combined signal is context-dependent rather than uniformly additive' is hedged appropriately but could be tightened to specify which context (population health status, dose, duration) the memo identifies as the moderator.
• The 'Why this is surprising' framing is reasonable but could briefly note that the headline contrast is dose-dependent (250 mg vs. 500-1000 mg) as well as population-dependent, since the memo already raises dose as a boundary condition.

Reviewer note

This is a clean, bounded two-receipt alpha memo that correctly identifies a real tension in the literature: a safety/feasibility pilot (Receipt 1) that does not support an additive claim, and a smaller RCT (Receipt 2) that suggests potential blunting of exercise-induced cardiovascular gains at 250 mg/day. The memo's caveats are appropriate, the falsifier is concrete and actionable, and both receipts exist and directly support the claims made. The main issue is title/source alignment: the title frames the signal as a 'protocol mismatch,' but the receipts differ substantially in population (functional limitations vs. healthy inactive aged men), dose (250 mg vs. 500-1000 mg), and duration (8 vs. 12 weeks). The memo itself acknowledges these as boundary conditions, so the title under-describes the contrast rather than mis-anchoring it on a non-resveratrol or non-exercise receipt. This is a fixable bounded edit. Also, 'matched RCT' in the abstract misdescribes Receipt 2. With a title that names the population/dose boundary and a corrected abstract descriptor, this memo meets the accept threshold; in its current form it is a competent-but-fixable revise.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: fallback_tiebreak_failed_conservative

Prompt: reviewer-v11-research-synthesis